Browse the evidence

Inter- and intradevice variation exists between DXA instruments, affecting data analysis in clinical trials.

Practitioners should be aware of potential measurement variability when using DXA in clinical trials.

Quality control procedures should be implemented prior to initiating clinical trials using DXA.

Implementing quality control can enhance the reliability of DXA measurements in trials.

Inter- and intrascan variability can be compounded by the patient population being investigated.

Understanding patient population effects can improve the interpretation of DXA results.

The percentage of body fat in the extremities was significantly lower in men with HIV lipodystrophy compared to both HIV-infected and healthy controls.

Clinicians should assess extremity fat in HIV-infected patients to identify potential lipodystrophy.

HIV-infected men without clinical evidence of lipodystrophy also had a significantly greater percentage of total body fat in the trunk and a significantly lower percent of body fat in the extremities compared to healthy controls.

Monitoring body fat distribution in HIV-infected men is crucial for identifying metabolic changes.

The number of adults with diabetes globally increased from 108 million in 1980 to 422 million in 2014.

Healthcare practitioners should be aware of the significant increase in diabetes prevalence when planning interventions.

Worldwide age-standardized adult diabetes prevalence doubled from 4.3% to 9.0% in men and from 5.0% to 7.9% in women.

This information is crucial for public health initiatives targeting diabetes prevention and management.

Few companies in the US reduced portion sizes of ultra-processed foods since 2002.

Practitioners should be aware that portion sizes of ultra-processed foods have not decreased significantly, which may impact dietary recommendations.

Reduced fat-free mass (FFM) is not the sole explanation for the lower energy expenditure seen in patients with PWS.

Practitioners should consider multiple factors affecting energy expenditure in PWS patients.

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.

Metformin failed to prove beneficial effects in MASLD progression.

Avoid using metformin for treating MASLD progression as it has not shown benefits.

Adipocyte and preadipocyte formation in scABD and scFEM depots correlates positively with VAT/TAT.

Understanding the relationship between adipocyte formation and VAT/TAT can inform strategies for managing obesity.

BAT thermal activity does not change in response to overfeeding.

Overfeeding does not affect BAT thermal activity in men.

BAT thermal activity does not correlate with the degree of metabolic adaptation.

BAT activity does not influence metabolic adaptation to overfeeding.

Glucose is essential for the functioning of the pentose phosphate pathway (PPP) and cannot be substituted by other metabolites.

Practitioners should recognize the critical role of glucose in metabolic pathways.

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

Semaglutide improves the function and inflammatory status of endothelial progenitor cells (EPCs) by inhibiting LPS-induced macrophage expression of miR-155 in exosomes.

Semaglutide may be beneficial in improving endothelial function in obesity-related inflammation.

LPS-induced macrophage exosomes reduce the cellular activity, migratory capacity, and tube-forming ability of EPCs.

Inflammation from macrophage exosomes can impair endothelial repair mechanisms.

Inhibition of miR-155 expression in macrophages improves EPC viability and reduces inflammation.

Targeting miR-155 may be a therapeutic strategy to enhance endothelial repair in obesity.

Women with PCOS exhibited approximately 80% lower expression of perilipins PLIN1, PLIN3, and PLIN5 compared to controls.

Women with PCOS may have impaired lipolysis due to lower perilipin expression.

Chocolate milk did not enhance skeletal muscle hypertrophy following training.

Chocolate milk is not an effective supplement for enhancing muscle growth post-training.